ClinicalTrials.gg

Program

zumilokibart

In AbbVie's pipeline, IL-13. Its studies are mostly in Dermatitis, Atopic · Asthma, led by AbbVie.

Furthest: phase 2, since Apr 29, 20244 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie44 open or runningphase 2since Apr 29, 2024Apr 29, 2024Nov 2026phase 2 · NCT06395948
  • Named in AbbVie’s own pipeline as Zumilokibart, phase 2, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2024First study: phase 2 study in Dermatitis, AtopicFirst studyNCT06395948 · 470 enrolled · United States, Canada, Czechia and more
  2. Mar 27, 2025Phase 1 study in AsthmaNCT06920901 · 31 enrolled · United States, United Kingdom
  3. May 26, 2025Phase 2 study in Dermatitis, AtopicNCT07003425 · 350 planned · United States, Canada, Czechia and more
  4. Jun 11, 2025Phase 1 study in Dermatitis, AtopicNCT07027527 · 86 enrolled · Australia, Canada, New Zealand

Ahead

  1. Nov 2026Primary completion: phase 2 study in Dermatitis, AtopicNCT06395948
  2. Dec 2029Primary completion: phase 2 study in Dermatitis, AtopicNCT07003425

TargetBeta

“IL-13”the company's pipeline, read by Claude · source

Other programs on IL13

ProgramCompanyFurthest phaseStudies
lebrikizumabruleEli Lillyphase 444
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
ompekimigPfizerphase 23
GHZ339Novartisphase 21
ABBV-313AbbViephase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07027527Dermatitis, Atopic · Australia, Canada, New Zealand1Active, not recruitingAug 29, 202686
NCT07003425Dermatitis, Atopic · United States, Canada, Czechia and more2RecruitingDec 2029350
NCT06920901Asthma · United States, United Kingdom1Active, not recruitingSep 17, 202631
NCT06395948Dermatitis, Atopic · United States, Canada, Czechia and more2Active, not recruitingNov 2026470

How it is read

Names in the registry

  • “APG777”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.